Reshaping the tumor microenvironment by degrading glycoimmune checkpoints Siglec-7 and -9

Chao Wang,Yingqin Hou,Jaroslav Zak,Qinheng Zheng,Kelli A. McCord,Mengyao Wu,Ding Zhang,Shereen Chung,Yujie Shi,Jinfeng Ye,Yunlong Zhao,Stephanie Hajjar,Ian A. Wilson,James C. Paulson,John R. Teijaro,Xu Zhou,Barry K. Sharpless,Matthew S. Macauley,Peng Wu

DOI: https://doi.org/10.1101/2024.10.11.617879

2024-10-12

Abstract:Cancer treatment has been rapidly transformed by the development of immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1. However, many patients fail to respond, especially those with an immunosuppressive tumor microenvironment (TME), suggesting the existence of additional immune checkpoints that act through orthogonal mechanisms. Sialic acid-binding immunoglobulin-like lectin (Siglec)-7 and -9 are newly designated glycoimmune checkpoints that are abundantly expressed by tumor-infiltrating myeloid cells. We discovered that T cells express only basal levels of Siglec transcripts; instead, they acquire Siglec-7 and -9 from interacting myeloid cells in the TME via trogocytosis, which impairs their activation and effector function. Mechanistically, Siglec-7 and -9 suppress T cell activity by dephosphorylating T cell receptor (TCR)-related signaling cascades. Using sulfur fluoride exchange (SuFEx) click chemistry, we developed a ligand that binds to Siglec-7 and -9 with high-affinity and exclusive specificity. Using this ligand, we constructed a Siglec-7/9 degrader that targets membrane Siglec-7 and -9 to the lysosome for degradation. Administration of this degrader induced efficient Siglec degradation in both T cells and myeloid cells in the TME. We found that Siglec-7/9 degradation has a negligible effect on macrophage phagocytosis, but significantly enhances T cell anti-tumor immunity. The degrader, particularly when combined with anti-CTLA-4, enhanced macrophage antigen presentation, reshaped the TME, and resulted in long-lasting T cell memory and excellent tumor control in multiple murine tumor models. These findings underscore the need to consider exogenous checkpoints acquired by T cells in the TME when selecting specific checkpoint blockade therapy to enhance T cell immunity.

Immunology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to reshape the tumor microenvironment by degrading the sialic - acid - binding immunoglobulin - like lectins (Siglec) - 7 and - 9 in the tumor microenvironment, so as to enhance the anti - tumor immune function of T cells. Specifically, the researchers found that T cells obtain Siglec - 7 and - 9 from myeloid cells through trogocytosis in the tumor microenvironment, and the expression of these receptors will inhibit the activation and effector functions of T cells. Therefore, the researchers developed a molecule that can specifically bind to and degrade Siglec - 7 and - 9, aiming to restore the function of T cells, thereby enhancing the anti - tumor immune response.

The main contributions of the paper include:
1. **Discovery that T cells obtain Siglec - 7 and - 9 through trogocytosis**: Through single - cell RNA sequencing, immunofluorescence staining and other techniques, the researchers found that T cells obtain Siglec - 7 and - 9 receptors through direct contact with myeloid cells in the tumor microenvironment.
2. **Development of high - affinity and specific Siglec - 7/9 ligands**: Using sulfur - fluorine exchange (SuFEx) click chemistry technology, the researchers synthesized high - affinity ligands that can specifically bind to Siglec - 7 and - 9.
3. **Construction of Siglec - 7/9 degrading agents**: Based on the above ligands, the researchers further developed molecules that can target and degrade Siglec - 7 and - 9. These molecules guide Siglec - 7 and - 9 to lysosomes for degradation.
4. **Verification of the effects of degrading agents in vitro and in vivo**: In vitro experiments, the researchers confirmed that the degrading agents can effectively degrade Siglec - 7 and - 9 and restore the activation and effector functions of T cells. In vivo experiments, through a mouse tumor model, the researchers verified that the degrading agents can significantly enhance the anti - tumor immune response of T cells and improve the tumor control effect.

In conclusion, through in - depth research on the mechanism of Siglec - 7 and - 9 in the tumor microenvironment, this paper proposes a new strategy to enhance the anti - tumor immune function of T cells, which has important clinical application potential.